Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients

Annals of Otology, Rhinology and Laryngology

Volumn 106, Issue 5, 1997, Pages 364-369

  Chevalier, Dominique ^a,c   Laccourreye, Ollivier ^b   Laccourreye, Henri ^b   Brasnu, Daniel ^b   Piquet, Jean Jacques ^a  

^a UNIV LILLE   (France)

^b Hopital Laennec   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

cricohyoidoepiglottopexy; glottic squamous cell carcinoma; partial laryngeal surgery

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLOTTIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARYNGECTOMY; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

EID: 0030984820     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/000348949710600502     Document Type: Article

References (34)

1. Harwood AR, De Boer G. Prognostic factor in T2 glottic cancer. Cancer 1980;45:991-5.
2. Wang CC. Factors influencing the success of radiation therapy for T2 and T3 glottic carcinomas. Am J Clin Oncol 1986;95:17-20.
3. Mendenhall WM, Parsons JT, Million RR, Fletcher GH. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiation therapy: relationship of dose-fractionation factors to local control and complications. Int J Radiat Oncol Biol Phys 1988;15:1267-73.
4. Howell-Burke D, Peters LJ, Goepfert H, Oswald MJ. T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. Arch Otolaryngol Head Neck Surg 1990;116:830-5.
5. Wiggenraad RG, Terhaard CH, Hordijik GJ, Ravasz LA. The importance of vocal cord mobility in T2 laryngeal cancer. Radiother Oncol 1990;18:321-7.
6. Laccourreye O, Weinstein G, Brasnu D, Trotoux J, Laccourreye H. Vertical partial laryngectomy: a critical analysis of local recurrence. Ann Otol Rhinol Laryngol 1991;100:68-71.
7. Turesson I, Sandberg N, Mercke C, Johansson KA, Sandin I, Wallgren A. Primary radiotherapy for glottic laryngeal carcinoma stage I and II. Acta Oncol 1991;30:357-62.
8. Inoue T, Inoue T, Ikeda H, Teshima T, Murayama S. Prognostic factors of telecobalt therapy for early glottic carcinoma. Cancer 1992;70:2797-801.
9. Kirchner JA, Som ML. Clinical significance of fixed vocal cord. Laryngoscope 1971;81:1029-44.
10. Stewart JG, Brown JR, Palmer MK, Cooper A. The management of glottic carcinoma by primary irradiation with surgery in reserve. Laryngoscope 1975;85:1477-84.
11. Som ML. Cordal cancer with extension to vocal process. Laryngoscope 1979;85:12-28.
12. Harwood AR, Bryce DP, Rider WD. Management of T3 glottic cancer. Arch Otolaryngol 1980;106:697-9.
13. Skolyszewski J, Reinfuss M. The results of radiotherapy of cancer of the larynx in six European countries. Radiobiol Radiother 1981;22:32-43.
14. Kessler DJ, Trapp KT, Calcaterra TC. Treatment of T3 glottic carcinoma with vertical partial laryngectomy. Arch Otolaryngol Head Neck Surg 1987;13:1196-9.
15. Robson NLK, Oswal VH, Flood LM. Radiation therapy of laryngeal cancer: a twenty year experience. J Laryngol Otol 1990;104:699-703.
16. Parsons T, Mendenhall WM, Stringer SP, Cassisi NJ, Million RR. Twice a day radiotherapy for squamous cell carcinoma of the head and neck: the University of Florida experience. Head Neck 1993;15:87-96.
17. Hendrickson FR. Radiation treatment of larynx cancers. Cancer 1985;55:2058-61.
18. Viani L, Stell PM, Dalby JE. Recurrence after radiotherapy for glottic carcinoma. Cancer 1991;67:577-84.
19. Majer H, Rieder A. Technique de la laryngectomie permettant de conserver la permeabilite respiratoire: la crico-hyoidopexie. Ann Otolaryngol Chir Cervicofac 1959;76:677-83.
20. Piquet JJ, Desaulty A, Decroix G. Crico-hyoido-epiglottopexie: technique operatoire et resultats fonctionnels. Ann Otolaryngol Chir Cervicofac 1974;91:681-90.
21. Laccourreye O, Crevier-Buchmann L, Weinstein G, Biacabe B, Laccourreye H, Brasnu D. Duration and frequency characteristics of speech and voice following supracricoid partial laryngectomy. Ann Otol Rhinol Laryngol 1995;104:516-21.
22. Beahrs OH, Henson DE, Hutter RVP, Myers M, eds. American Joint Committee on Cancer. Manual for staging of cancer. 3rd ed. Philadelphia, Pa: JB Lippincott, 1988:39-44.
23. Laccourreye O, Weinstein G, Brasnu D, et al. A clinical trial of continuous cisplatin-fluorouracil induction chemotherapy and supracricoid partial laryngectomy for glottic carcinoma classified as T2. Cancer 1994;74:2781-90.
24. Laccourreye H, Laccourreye O, Weinstein G, Menard M, Brasnu D. Supracricoid laryngectomy with cricohyoidoepiglottopexy: a partial laryngeal procedure for glottic carcinoma. Ann Otol Rhinol Laryngol 1990;99:421-6.
25. Piquet JJ, Chevalier D. Subtotal laryngectomy with cricohyoidoepiglottopexy for the treatment of extended glottic carcinomas. Am J Surg 1991;162:357-61.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
27. Olofsson J, Lord IJ, van Nostrand AWP. Vocal cord fixation in laryngeal carcinoma. Acta Otolaryngol (Stockh) 1973;75:496-510.
28. Hirano M, Kurita S, Matsuoka H, Tateishi M. Vocal cord fixation in laryngeal carcinomas. Acta Otolaryngol (Stockh) 1991;111:449-54.
29. Soo KC, Shah JP, Gopinath KS, Jacques DP, Gerold FP, Strong EW. Analysis of prognostic variables and results after vertical partial laryngectomy. Am J Surg 1988;156:264-8.
30. Johnson JT, Myers EN, Hao S-P, Wagner RL. Outcome of open surgical therapy for glottic carcinoma. Ann Otol Rhinol Laryngol 1993;102:752-5.
31. Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Stringer SP, Million RR. Twice-a-day radiotherapy for T3 squamous cell carcinoma of the glottic larynx. Head Neck 1989;11:123-8.
32. Laccourreye O, Bassot V, Naudo P, Jouffre V, Brasnu D, Laccourreye H. Chimiotherapie cisplatine-fluorouracile dans les cancers épidermoides à point de départ glottique classes T2. Ann Otolaryngol Chir Cervicofac 1994;111:281-91.
33. Laccourreye O, Bassot V, Brasnu D, Jouffre V, Menard M, Laccourreye H. Chimiotherapie exclusive dans les cancers de la corde vocale T1-T3 N0 en réponse clinique complete après traitement neo-adjuvant cisplatine fluorouracile. Presse Med 1995;24:1337-40.
34. Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D, Laccourreye H. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3 N0 glottic squamous cell carcinoma complete clinical responders. 5-year results. J Clin Oncol 1996; 14:2331-6.